Maxigen Biotech Financials
| 1783 Stock | TWD 44.60 1.15 2.65% |
Maxigen |
Understanding current and past Maxigen Biotech Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Maxigen Biotech's financial statements are interrelated, with each one affecting the others. For example, an increase in Maxigen Biotech's assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Maxigen Biotech's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Maxigen Biotech. Check Maxigen Biotech's Beneish M Score to see the likelihood of Maxigen Biotech's management manipulating its earnings.
Maxigen Biotech Stock Summary
Maxigen Biotech competes with Phytohealth Corp, Orient Pharma, and Yung Zip. Maxigen Biotech Inc. engages in the development, manufacture, and marketing of biomedical and cosmeceutical skincare products in Taiwan and internationally. Maxigen Biotech Inc. was founded in 1998 and is based in Taoyuan, Taiwan. MAXIGEN BIOTECH is traded on Taiwan Stock Exchange in Taiwan.| Foreign Associate | Malaysia |
| Instrument | Taiwan Stock View All |
| Exchange | Taiwan Stock Exchange |
| ISIN | TW0001783009 |
| Business Address | No 88, Keji |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Major |
| Benchmark | Dow Jones Industrial |
| Website | mbi-bio.com |
| Phone | 886 3 328 7222 |
| Currency | TWD - New Taiwan Dollar |
You should never invest in Maxigen Biotech without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Maxigen Stock, because this is throwing your money away. Analyzing the key information contained in Maxigen Biotech's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Maxigen Biotech Key Financial Ratios
There are many critical financial ratios that Maxigen Biotech's investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Maxigen Biotech reports annually and quarterly.| Return On Equity | 0.0926 | |||
| Return On Asset | 0.0454 | |||
| Number Of Employees | 20 | |||
| Beta | 1.05 |
Maxigen Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Maxigen Biotech's current stock value. Our valuation model uses many indicators to compare Maxigen Biotech value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Maxigen Biotech competition to find correlations between indicators driving Maxigen Biotech's intrinsic value. More Info.Maxigen Biotech is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers reporting about 0.49 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Maxigen Biotech is roughly 2.04 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Maxigen Biotech's earnings, one of the primary drivers of an investment's value.Maxigen Biotech Systematic Risk
Maxigen Biotech's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Maxigen Biotech volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was ten with a total number of output elements of fifty-one. The Beta measures systematic risk based on how returns on Maxigen Biotech correlated with the market. If Beta is less than 0 Maxigen Biotech generally moves in the opposite direction as compared to the market. If Maxigen Biotech Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Maxigen Biotech is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Maxigen Biotech is generally in the same direction as the market. If Beta > 1 Maxigen Biotech moves generally in the same direction as, but more than the movement of the benchmark.
Maxigen Biotech Thematic Clasifications
Maxigen Biotech is part of IT investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. Information technology and IT services. Information Technology (IT) companies and IT service providers across different domains
This theme covers Information technology and IT services. Information Technology (IT) companies and IT service providers across different domains. Get More Thematic Ideas
| IT | View |
Maxigen Biotech November 30, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Maxigen Biotech help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Maxigen Biotech. We use our internally-developed statistical techniques to arrive at the intrinsic value of Maxigen Biotech based on widely used predictive technical indicators. In general, we focus on analyzing Maxigen Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Maxigen Biotech's daily price indicators and compare them against related drivers.
| Information Ratio | (0.15) | |||
| Maximum Drawdown | 6.36 | |||
| Value At Risk | (2.32) | |||
| Potential Upside | 2.65 |
Additional Tools for Maxigen Stock Analysis
When running Maxigen Biotech's price analysis, check to measure Maxigen Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Maxigen Biotech is operating at the current time. Most of Maxigen Biotech's value examination focuses on studying past and present price action to predict the probability of Maxigen Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Maxigen Biotech's price. Additionally, you may evaluate how the addition of Maxigen Biotech to your portfolios can decrease your overall portfolio volatility.